Table 1. Baseline characteristics.
| ICO/CLX (n = 95) |
ICO/FF (n = 112) |
ICO/FFPE (n = 163) | MECC (n = 270) |
|
|---|---|---|---|---|
| Gender | ||||
| Male | 67 (70.5%) | 63 (56.3%) | 103 (63.2%) | 145 (53.7%) |
| Female | 28 (29.5%) | 49 (43.7%) | 60 (36.8%) | 125 (46.3%) |
| Age | ||||
| Median (range) years | 72 (43–87) | 69 (32–92) | 67 (37–87) | 73 (24–93) |
| Site | ||||
| Right | 38 (40%) | 49 (43.7%) | 64 (39.3%) | 96 (35.6%) |
| Left | 57 (60%) | 63 (56.3%) | 99 (60.7%) | 172 (63.7%) |
| Unknown | 2 (0.8%) | |||
| Stage | ||||
| IIA | 87 (91.6%) | 100 (89.3%) | 133 (81.6%) | 261 (97%) |
| IIB | 8 (8.4%) | 12 (10.7%) | 30 (18.4%) | 9 (3%) |
| Lymph node assessed | ||||
| Median (range) | 18 (2–49) | 23 (3–73) | 18 (2–83) | |
| Microsatellite instability | ||||
| MSI | 0 | --- | 20 (12.3%) | 22 (8.1%) |
| MSS | 95 (100%) | --- | 120 (73.6%) | 248 (91.9%) |
| Unknown | 112 (100%) | 23 (14.1%) | ||
| Recurrencea | ||||
| Event | 22 (23.2%) | 21 (18.75%) | 24 (14.7%) | 56 (20.7%) |
| No event | 73 (76.8%) | 91 (81.25%) | 139 (85.3%) | 214 (79.3%) |
| Recurrence-free time Median (range) months |
63 (7–137) |
65 (0.2–234) |
66 (0.4–210) |
80 (0.9–222) |
| Pathology assessment mean (range) |
||||
| TILs | 1.2 (0–8.8) | --- | --- | 1.6 (0–46) |
| STLs (%) | 17.6 (5–88) | --- | --- | --- |
| Stroma/Tumor % | 44.4 (10–90) | --- | --- | --- |
aRecurrence for ICO and death related to CRC for MECC.
CLX, Colonomics Study; CRC, colorectal cancer; FF, fresh frozen; FFPE, formalin-fixed paraffin-embedded; ICO, Catalan Institute of Oncology; MECC, Molecular Epidemiology of Colorectal Cancer Study, STL, stromal lymphocyte; TIL, tumor-infiltrating lymphocyte.